The White House is examining a new prescription drug user-fee agreement between the FDA and the biopharma industry that would set fee levels for 2028 through 2032. Sources indicate the framework is under review, with implications for how FDA resources are funded to support review timelines and regulatory capacity. Because user-fee amounts directly affect FDA operations, the review signals that final fee levels could drive downstream expectations around review speed and throughput for novel therapies entering development. The next user-fee deal is a central lever for industry planning, influencing budgeting and timelines across clinical development programs.